Abivax Releases the Results of its November 9, 2022 Ad Hoc Ordinary and Extraordinary General Meeting
Shareholders approved all proposed resolutions PARIS, FRANCE / ACCESSWIRE / November 15, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held an ad hoc ordinary and…
bubmagNovember 15, 2022